我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

辅助阿托伐他汀钙治疗对扩张型心肌病患者心功能及血清Cys-C的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第5期
页码:
558-561,574
栏目:
临床研究
出版日期:
2018-06-25

文章信息/Info

Title:
Effect of atorvastatin on cardiac function and serum Cys-C in patients with dilated cardiomyopathy
作者:
陈 慧; 李 敏; 刘 蕾; 党夏薇; 朱丹军; 田 刚
（西安交通大学第一附属医院心内科，陕西 西安 710061）
Author(s):
CHEN Hui;  LI Min;  LIU Lei;  DANG Xia-wei;  ZHU Dan-jun;  TIAN Gang
(Department of Cardiology, the First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an 710061, Shaanxi, China)
关键词:
心肌病; 扩张型; 阿托伐他汀钙; 心功能; 血清胱抑素C
Keywords:
dilated cardiomyopathy;  atorvastatin calcium;  cardiac function;  serum cystatin C
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的 观察辅助阿托伐他汀钙治疗对扩张型心肌病（DCM）患者心功能及血清胱抑素(Cys)-C影响。方法 选取住院的48例心功能II~IV级DCM患者，测定患者心脏超声参数、血浆氨基末端脑钠尿肽前体（NT-proBNP）及血清Cys-C等血清生化指标，将患者随机分为常规试药组（对照组，27例）及辅助阿托伐他汀钙试药组（试药组，21例），后者在常规治疗基础上联用阿托伐他汀钙20 mg/d，治疗12个月后测定并比较两组心超参数及Cys-C等血清生化指标。结果 ①试药组治疗12个月后心功能改善程度优于对照组（P<0.01），左室舒张末内径（LVEDD）、血清NT-proBNP及Cys-C水平低于对照组（P<0.05,P<0.01）；②DCM患者血清Cys-C水平与左室射血分数（LVEF）、NT-proBNP、血肌酐（SCr）及肾小球滤过率（GFR）呈强相关性（P<0.01）。结论 长期常规剂量辅助阿托伐他汀钙治疗可改善DCM患者心功能，逆转心肌重构，该作用可能与其下调患者血清Cys-C水平相关。
Abstract:
AIM To observe the effect of atorvastatin on cardiac function and serum cystatin (Cys)-C in patients with dilated cardiomyopathy (DCM). METHODS Forty-eight patients with DCM (NYHA cardiac function grade:II-IV) were chosen to evaluate echocardiography parameters, plasma N-terminal pro-B-type natriuretic peptide(NT-proBNP), serum Cys-C, and other serum biochemical indexes from October 2011 to January 2015. Patients were randomly divided into a routine treatment group (control group, n=27) and an auxiliary atorvastatin treatment group (treatment group, n=21),and the treatment group received atorvastatin 20 mg/d plus routine therapy, the other received routine therapy only. 12 months later, echocardiography parameters, Cys-C, and other serum biochemical indexes were measured and compared. RESULTS After 12 months of treatment, the heart function of the treatment group were significantly improved when compared to the control group (P<0.01). Left ventricular end diastolic diameter (LVEDD), serum NT-proBNP, and Cys-C levels were lower than the control group (P<0.05, P<0.01); The serum Cys-C levels were strongly correlated with left ventricular ejection fraction (LVEF), serum creatinine (SCr), NT-proBNP, and glomerular filtration rate (GFR) in patients with DCM (P<0.01). CONCLUSION Long term treatment with atorvastatin calcium in routine doses improved heart function and reversed myocardial remodeling in patients with DCM. This beneficial effect may be related to reduction of serum levels of Cys-C.

参考文献/References

[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.心肌病诊断与治疗建议[J].中华心血管病杂志,2007,35(1):5-16.

[2]Youssel S,Stuve O,Patarroyo JC,et al.The HMG-CoA reductase inhibitor，atorvastatin,promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease[J].Nature,2002,420（1）:78-84.

[3]Node K,Fujita M,Kitakaze M,et al.Short-Term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy[J].Circulation,2003,108(7): 839-843.

[4]肖立中,林晓云,马绍椿,等.阿托伐他汀对扩张型心肌病患者心功能及心率变异性的影响[J].临床心血管病杂志,2004,20(3):133-135.

[5]Djousse L,Kurth T,Gaziano JM.Cystatin C and risk of heart failure in the Physicians'Health Study (PHS)[J].Am Heart J,2008,155(1):82-86.

[6]朱志芳,于占文,郝兆星.慢性心力衰竭患者血清胱抑素C与心室重构的相关性[J].中国医师杂志,2014,16(3):396-398.

[7]高 阳,杨国杰.老年心衰患者血清胱抑素C与心室重构的相关性[J].中国老年学杂志,2012,32(18):3890-3891.

[8]Bielecka-Dabrowa A,Mikhailidis DP,Rizzo M,et al.The influence of atorvastatin on parameters of inflammation left ventricular function,hospitalizations and mortality in patients with dilated cardiomyopathy-5-year followup[J].Lipids Health Dis,2013,12:47.

[9]孔祥勇,胡世莲,沈 干,等.阿托伐他汀治疗扩张型心肌病伴慢性充血性心力衰竭患者疗效的Meta分析[J].中国循证医学杂志,2012,12(10):1223-1228.

[10]Xie L,Terrand J,Xu B,et al.Cystatin C increases in cardiac injury:a role in extracellular matrix protein modulation[J].Cardiovasc Res,2010,87(4):628-635.

[11]陆治平,黄 进.阿托伐他汀对CHF患者血清胱抑素C、心肾及炎性指标的影响[J].中华全科医学,2013,11(4):542-588.

[12]Ashton E,Windebank E,Skiba M,et al.Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study[J].Int J Cardiol,2011,146(3):404-407.

[13]Kjekshus J,Apetrei A,Barrios V,et al.and for the CORONA Group.Rosuvastatin in older patients with systolic heart failure[J].N Engl J Med,2007,357(22):2248-2261.

[14]Tavazzi L,Maggioni AP,Marchioli R,et al.Gissi-HF Investigators.Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial):a randomised,double-blind,placebo-controlled trial[J].Lancet,2008,372(9645):1231-1239.

[15]Desai RV,Banach M,Ahmed MI,et al.Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial)[J].Am J Cardiol,2010,106(2):221-227.

[16]Domanski M,Coady S,Fleg J,et al.Effect of statin therapy on survival in patient with nonischemic dilated cardiomyopathy(from the Beta- blocker Evaluation of Survival Trial[BEST])[J].Am J Cardiol,2007,99(10):1448-1450.

[17]Martin J,Denver R,Bailey M,et al.In vitro inhibitory effects of atorvastatin on cardiac fibroblasts:implications for ventricular remodeling[J].Clin Exp Pharmacol Physiol,2005,32(9):697-701.

[18]Xian-zhi H,Sheng-hua Z,Xin-hong W,et al.The effect of early and intensive statin therapy on ventricular premature beat or non-sustained ventricular tachycardia in patients with acute coronary syndrome[J].Cardiol J,2010,17(4):381-385.

备注/Memo

备注/Memo:
收稿日期：2017-11-09.基金项目：国家“973”科技支撑计划项目资助（2011BAI11B23） 通讯作者：朱丹军，副主任医师，主要从事心律失常和电生理研究 Email：zhudanjun9@hotmail.com 共同通讯作者：田刚，主任医师，主要从事高血压和冠心病治疗研究 Email：tiangang36@yahoo.com 作者简介：陈慧，博士生 Email：hui.1989.12.18@stu.xjtu.edu.cn
更新日期/Last Update: 1900-01-01